Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer
Sponsor: Manyak, Michael, M.D.
Terminated
Withdrawal of funding support
A PHASE4 clinical study on Prostate Cancer, this trial is terminated or withdrawn. The trial is conducted by Manyak, Michael, M.D. and has accumulated 6 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE4
First recorded
Sep 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Manyak, Michael, M.D.
- Pharmatech
- Watson Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .